Showing results for: Molecular Diagnostics Articles & Analysis

Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, has announced the closing of a definitive asset purchase agreement under which Flagship Biosciences, Inc. has acquired the Company’s Pharma Services business (Interpace Pharma Solutions). The Company will use the proceeds from the transaction for ...

By Interpace Biosciences

Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), has the honor to invite its shareholders, holders of subscription rights, holders of convertible bonds, directors and statutory auditor to its annual shareholders' meeting (‘AGM’) that will be held on Friday 13 May 2022 at 2:00 p.m. CEST at ...

By Biocartis NV

Anavasi Diagnostics ('Anavasi'), a medical technology company focused on the development of novel molecular diagnostic testing, has announced the addition of Scott Robitaille as Vice President of Sales & Marketing. Robitaille joins Anavasi with in-depth knowledge of the medical device and molecular diagnostics sector and over two decades of sales, marketing, and channel management ...

By Anavasi Diagnostics

Research Triangle Park, North Carolina, December 31st, 2020 – Redbud Labs (“Redbud”) closed out an active year for new product development. Early in 2020, Redbud Labs announced its ISO certification and an expansion of its product lines. Responding to the COVID-19 outbreak, Redbud adjusted its operating plans and began new internal R&D projects. The company’s ...

By Redbud Labs

Anavasi Diagnostics announced today that it has submitted the required EUA Clinical Study Data for the AscencioDx®, the molecular diagnostic platform for the detection of RNA indicative of the presence of the SARS-CoV-2/COVID-19 virus, to the Food and Drug Administration (FDA). Anavasi is a medical technology company focused on the development of novel molecular diagnostic testing. It uses a ...

By Anavasi Diagnostics

HiberGene Diagnostics, the leading manufacturer of molecular diagnostics products in Ireland, is pleased to announce that it will supply its innovative point-of-care (POC) and near-patient testing solutions directly to healthcare providers in the UK and Ireland. These high-quality testing solutions cover infectious and transmissible disease areas – including respiratory, sexually ...

By HiberGene Diagnostics

ELITechGroup Molecular Diagnostics announce today the CE-IVD marking of the CRE ELITe MGB kit, a high-performance, qualitative, multiplex assay for the rapid detection of the Carbapenem Resistance genes of Enterobacteriaceae. In combination with the ELITe InGenius™, the ELITech Group’s fully automated sample-to-result system, the assay is intended to detect 150 variants belonging to ...

By ELITechGroup

Quadrant Biosciences Inc., a developer of novel molecular diagnostic tools, has been granted a Breakthrough Device designation by the Center of Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for its innovative Clarifi ASD® autism saliva test. Clarifi ASD is indicated for use in assessing the likelihood that a child has autism spectrum disorder (ASD) based on ...

By Quadrant Biosciences Inc.

BillionToOne , Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announces the launch of their UNITY fetal antigen single-gene non-invasive prenatal test (sgNIPT), a new addition to UNITY Screen. For pregnant patients who are alloimmunized with C, c, D, E, Duffy (Fya), or Kell (K) red blood cell (RBC) antibodies, this novel NIPT ...

By BillionToOne Inc.

DR CHENG BOON, ONCOLOGIST IN THE PRIVATE SECTOR AND THE NHS AS WELL AS ACTING AS ONCODNA UK MEDIAL DIRECTOR COMMENTED: “In my view, this is an important first step in a collaboration that will make it much easier for public and privately practising oncologists to access biopsy tissue and request ONCODEEP* for the purpose of routine next generation sequencing. This unique public-private ...

By OncoDNA S.A.

Inflammatix, a pioneering molecular diagnostics company, announced today the appointment of Kian Beyzavi, PhD, as an independent member of the company’s board of directors. Dr. Beyzavi is a seasoned veteran of the healthcare industry with significant operating experience in the medical device and diagnostics industries, and a focus on leveraging innovative technologies to improve diagnosis ...

By Inflammatix, Inc.

FUSION GENOMICS Corporation is a molecular diagnostic company that develops clinical assays using next-generation sequencing technologies to characterize infectious disease agents of clinical and global importance. We are looking to hire a full-time Postdoctoral Fellow to join our team in an exciting and highly dynamic start-up environment. FUSION GENOMICS is looking for a passionate, self ...

By Fusion Genomics Corporation

Great Basin Scientific, a molecular diagnostics company, and Dr. Todd Treangen’s bioinformatics group in the Department of Computer Science at Rice University (www.treangenlab.com), today announced a co-development partnership that is optimizing the design and in silico evaluation of molecular detection assays for the SARS-CoV-2 viral RNA, the pathogen that causes COVID-19. The aim of the ...

By Great Basin Scientific

Self-screen is proud to announce the appointment of Michelle Meijer, PhD, as the companies Chief Commercial Officer. Michelle brings over 25 years of business experience in the life sciences and molecular diagnostics field, of which more than 15 years in the field of cervical cancer prevention and HPV diagnostics in particular. She held several senior business development and management roles at ...

By Self-screen B.V.

Anavasi Diagnostics, a medical technology company focused on the development of novel molecular diagnostic testing using a proprietary patent-pending reverse transcriptase methodology, today announced it has been awarded $14.9 million from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative. The funding will accelerate the launch and broad market ...

By Anavasi Diagnostics

Vela Diagnostics has announced the development of the ViroKey SA201 2019-nCoV RT-PCR Test, a new test kit for the detection of the 2019 Novel Coronavirus (2019-nCoV), otherwise known as the Wuhan Coronavirus. The Wuhan Coronavirus was first identified in mid-December 2019 in Wuhan, China. Human-to-human transmission has been confirmed by China’s health ministry. According to Chinese health ...

By Great Basin Scientific

Molecular Health and the life science company Gen Era Diagnostics have signed a collaboration agreement to optimize the personalized treatment of patients with cancer. For this purpose, Gen Era will provide the MH Guide software platform to twenty laboratories in Turkey to use in the interpretation of tumor data. “We are pleased to have Molecular Health on board in the near future as an ...

By Molecular Health GmbH

Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced that its partner SkylineDx will present new data showing that its Merlin Test was able to prospectively reduce more than 37% of surgeries in a noninterventional study for newly diagnosed melanoma patients1 . The abstract publication ...

By Biocartis NV

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, issued the following statement from Douglas Bryant, Quidel’s President and CEO, regarding Quidel’s ongoing efforts to evaluate COVID-19 mutations and confirm that its antigen tests continue to detect COVID-19 ...

By Quidel Corporation

DiamiR, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, today announced that Dr. Kira Sheinerman, Chief Executive Officer, will be presenting and participating in a panel discussion at The 21st International Conference on Alzheimer's Drug Discovery hosted by the Alzheimer's Drug Discovery Foundation (ADDF) and held virtually October 5-6, ...

By DiamiR